



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 10, 2002

James F. McBride 43,784
Name of Attorney or Agent Registration No.

Signature of Attorney or Agent

175)

#5

P&G Case CM2174M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Richard Besselievre et al. : Confirmation No. 1314
Serial No. 10/019,179 : Group Art Unit not yet assigned
Filed December 21, 2001 : Examiner not yet assigned
For Process for Making Amine Compounds

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JUN 18 2002
TC 1700

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.



3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☒ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.


☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By



James H. McBride
Attorney or Agent for Applicant(s)
Registration No. 43,784
(513) 627-0079

Date: June 10, 2002

Customer No. 27752

(IDS.doc)
(Last Revised 12/7/01)

RECEIVED
JUN 18 2002
TC 1700




COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

| <u>Atty. Docket No.</u> | <u>Serial Number</u> | <u>Inventor(s)</u> | <u>Filing Date</u> |
|-------------------------|----------------------|--------------------|--------------------|
| CM2175 | 10/019,177 | Busch et al | December 21, 2001 |
| CM2176 | 10/019,178 | Busch et al. | December 21, 2001 |
| CM1857M2 | 09/720,394 | Bettiol et al. | July 12, 1999 |
| CM1856M2 | 09/720,395 | Bettiol et al. | July 12, 1999 |
| 5388RDD | 09/711,447 | Trinh et al. | November 13, 2000 |

RECEIVED
JUN 18 2002
TG 1700

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

| | |
|------------------------|----------------------------|
| Application Number | 10/019,179 |
| Confirmation Number | 1314 |
| Filing Date | 12/21/2001 |
| First Named Inventor | Richard Besselievre et al. |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | CM2174M |

U. S. PATENT DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | U.S. PATENT DOCUMENT Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|---|--------------------------------------|--|--|--|
| | 1 | 4,449,987 | | Lindauer | 5/22/1984 | |
| | 2 | 4,693,890 | | Wilson et al. | 9/15/1987 | |
| | 3 | 4,696,676 | | Wilson et al. | 9/29/1987 | |
| | 4 | 4,933,371 | | Hink et al. | 6/12/1990 | |
| | 5 | 5,030,660 | | Norris et al. | 7/9/1991 | |
| | 6 | 5,196,200 | | Wilson et al. | 3/23/1993 | |
| | 7 | 3,936,448 | | Lamberti | 2/3/1976 | |
| | 8 | 4,565,647 | | Llenado | 1/21/1986 | |
| | 9 | 5,188,753 | | Schmidt et al. | 2/23/1993 | |
| | 10 | 4,853,369 | | Mookherjee et al. | 8/1/1989 | |
| | 11 | 3,426,011 | | Parmerter et al. | 2/4/1969 | |
| | 12 | 3,453,257 | | " | 7/1/1969 | |
| | 13 | 3,453,258 | | " | 7/1/1969 | |
| | 14 | 3,453,259 | | " | 7/1/1969 | |
| | 15 | 3,453,260 | | " | 7/1/1969 | |
| | 16 | 3,459,731 | | Gramera et al. | 8/5/1969 | |
| | 17 | 3,553,191 | | Parmerter et al. | 1/5/1971 | |
| | 18 | 3,565,887 | | " | 1/5/1971 | |
| | 19 | 4,535,152 | | Szejtli et al. | 8/13/1985 | |
| | 20 | 4,616,008 | | Hirai et al. | 10/7/1986 | |
| | 21 | 4,678,598 | | Ogino et al. | 7/7/1987 | |
| | 22 | 4,638,058 | | Brandt et al. | 1/20/1987 | |
| | 23 | 4,746,734 | | Tsuchiyuama et al. | 5/24/1988 | |
| | 24 | 3,862,058 | | Nirschl et al. | 1/21/1975 | |
| | 25 | 3,948,790 | | Speakman | 4/6/1976 | |
| | 26 | 3,954,632 | | Gloss | 5/4/1976 | |
| | 27 | 4,062,647 | | Storm et al. | 12/13/1977 | |
| | 28 | 4,585,642 (equivalent of DE-A-3417649) | | Rieck | 4/29/1986 | |
| | 29 | 4,664,839 & 4,820,439 (equivalent of EP-A-0164514) | | Rieck | 5/12/1987 and 4/11/1989 | |
| | 30 | 4,950,310 (equivalent of DE-A-3742043) | | Rieck | 8/21/1990 | |
| | 31 | 4,174,291 (equivalent of DE 2321001) | | Benjamin et al. | 11/13/1979 | |



FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | FOREIGN PATENT DOCUMENT Office ² Number ³ Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|---|--|--|----------------|
| | 32 | GB 1,379,241 | Unilever | 1/2/1975 | | |
| | 33 | GB 1,389,732 (NL 7205873 same family) | " | 4/9/1975 | | |
| | 34 | GB 1,387,447 | Monsanto Co. | 3/19/1975 | | |
| | 35 | GB 1,261,829 | Unilever | 1/26/1972 | | |
| | 36 | GB 1,398,421 | " | 6/18/1975 | | |
| | 37 | GB 1,398,422 | " | 6/18/1975 | | |
| | 38 | GB 1,439,000 | " | 6/9/1976 | | |
| | 39 | GB 1,514,276 | " | 6/14/1978 | | |
| | 40 | GB 1,425,343 | " | 2/18/1976 | | |
| | 41 | EP 971 024 (EP apps 98870226.2 & 98870155.3) | A1 Procter & Gamble | 1/12/2000 | | |
| | 42 | EP 971 021 (EP apps 98870026.4 & 98870155.3) | A1 " | 1/12/2000 | | |
| | 43 | EP 971 026 (EP apps 98870025.6 & 98870155.3) | A1 " | 1/12/2000 | | |
| | 44 | EP 299 575 | B1 " | 1/12/1994 | | |
| | 45 | EP 011 340 | " | 11/24/1982 | | |
| | 46 | EP 659 876 | " | 6/28/1995 | | |
| | 47 | EP 313 146 | B2 " | 5/26/1993 | | |
| | 48 | EP 971 027 (EP app 98870227.0) | A1 " | 1/12/2000 | | |
| | 49 | JP 090040687 | Hasegawa Koryo, KK | 2/10/1997 | | X |
| | 50 | WO 95/04809 | A1 Firmenich, SA | 2/16/1995 | | |
| | 51 | WO 95/08976 | A1 Procter & Gamble | 4/6/1995 | | |
| | 52 | WO 96/05358 | A1 " | 2/22/1996 | | |
| | 53 | WO 98/40464 | A1 Unilever | 9/17/1998 | | |
| | 54 | WO 96/38528 (EP app 95303762.9) | Procter & Gamble | 12/5/1996 | | |
| | 55 | WO 96/04940 | A1 " | 2/22/1996 | | |
| | 56 | WO 95/10591 | A1 " | 4/20/1995 | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| EXAMINER INITIALS* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ⁶ |
|--------------------|-----------------------|--|-----------------|
| | 57 | Psychophysics and Perfumery, pp. 243-250 | |
| | 58 | Steffen Arctander, Perfume and Flavor Chemicals, Volumes I and II, 1969, Montclair, NJ USA | |
| | 59 | B.D. Mookherjee et al., <i>Semio Activity of Flavor and Fragrance Molecules on Various Insect Species</i> , Bioactive Volatile Compounds from Plants, ASC Symposium Series 525, 1993, pp. 35-48 | |
| | 60 | Compilation of Odor and Taste Threshold Values Data, F.A. Fazzalari ed., 1978 | |
| EXAMINER | | | DATE CONSIDERED |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.